Enhanced Cytosine Base Editing for Duchenne Muscular Dystrophy

A novel engineered TadA ortholog-derived cytosine base editor (aTdCBE) can overcome existing limitations in motif preferences and adenosine activity seen in current cytosine base editors (CBEs). The new base editor enables precise cytosine base editing without generating unwanted off-target effects, improving gene editing’s scope and efficiency in treating genetic disorders.

By: Gorm Palmgren - Sep. 17, 2024
News

The study addresses the challenge of tRNA-specific adenosine deaminase (TadA) variants showing dual activity on cytosine and adenosine bases. Using TadA ortholog screening and multi-sequence alignment, the Chinese researchers developed aTdCBE, which lacks adenosine deaminase activity.

The novel CBE was tested for its ability to correct exon 55 splicing in a humanised mouse model of Duchenne muscular dystrophy (DMD) with a deletion in exon 54 of the DMD gene. The deletion results in a premature stop codon in exon 55 and leads to the production of a non-functional dystrophin protein. The objective was to restore dystrophin expression by skipping exon 55 through precise cytosine base editing at the exon 55 splice acceptor site (SAS).

Six weeks after in vivo delivery of aTdCBE, DNA base editing at the exon 55 splice acceptor site was over 40%, indicating effective editing of the DMD gene. Immunostaining showed that dystrophin-positive muscle fibres reached almost 99% of wild-type levels, while western blot analysis confirmed about 60% restoration of dystrophin expression.

RT-PCR further confirmed successful exon 55 skipping, restoring the correct reading frame of the DMD gene. This led to the production of functional dystrophin protein, demonstrating efficient gene editing and significant dystrophin restoration in the treated mice.

This work was conducted by researchers from HuidaGene Therapeutics and elsewhere in China, and it was published yesterday in Nature Communications.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNewsHashtagIn vivoHashtagDuchenne Muscular Dystrophy, DMDHashtagBase editors

News: Enhanced Cytosine Base Editing for Duchenne Muscular Dystrophy
CLINICAL TRIALS
Beta-Thalassemia, BT, (NCT06328764)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT06565026)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine